Anti-α-fodrin antibodies in Sjögren’s syndrome and other autoimmune diseases: analysis of published reports
Anti-α-fodrin method | pSS | sSS | SLE | RA | MS | Controls | |
---|---|---|---|---|---|---|---|
SLE | RA | ||||||
Results are expressed as percentage. | |||||||
pSS, primary Sjögren’s syndrome; sSS, secondary Sjögren’s syndrome; SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; MS, multiple sclerosis. | |||||||
*pSS with neurological manifestations; †pSS without neurological manifestations, | |||||||
Witte et al8 | |||||||
Number | 85 | 15 | 7 | 50 | 12 | 160 | |
ELISA | ND | ||||||
IgA | 64 | 47 | 86 | 2 | 17 | <1 | |
IgG | 55 | 40 | 43 | 2 | 42 | 2 | |
Witte et al1 | |||||||
Number | 136 | 207 | |||||
ELISA | ND | ND | ND | ND | ND | ||
IgA | 78.7 | 2.9 | |||||
IgG | 66.2 | 3.4 | |||||
De Seze et al9,10 | |||||||
ELISA (n) | 84 | ND | ND | 38 | ND | 60 | 160 |
IgA or Ig G | 64.5*/73.6† | 15.8 | 13.3 | 6.3 | |||
Zandbelt et al4 | |||||||
ELISA (n) | 21 | 4 | ND | 6 | 12 | ND | 28 |
IgA | 43 | 75 | 0 | 8.3 | 0 | ||
IgG | 48 | 75 | 0 | 50 | 0 | ||
Ruffati et al5 | |||||||
ELISA (n) | 80 | ND | ND | 50 | 30 | ND | 60 |
IgA | 32.5 | 32 | 46.7 | 1.7 | |||
IgG | 21.3 | 26 | 13.3 | 8.3 | |||
Haneji et al6 | |||||||
Number | 43 | 8 | ND | 21 | 14 | ND | 15 |
Immnublotting | 95.4 | 87.5 | 0 | 0 | 0 | ||
Watanabe et al78] | |||||||
Number | 9 | 15 | ND | 44 | ND | ND | ND |
Immunoblotting | 78 | 60 | 7 | ||||
Nordmark et al3 | |||||||
Number | 56 | 14 | ND | ND | 53 | ND | ND |
Immunoprecipitation | 29 | 21 | 47 | ||||
Current report | |||||||
ELISA (normal <15 U/l) (n) | 107 | ND | ND | 32 | 43 | ND | 48 |
IgA | 17.7 | 25 | 23.3 | 12.5 | |||
IgG | 5.6 | 21.8 | 2.32 | 0 | |||
Home made (normal (0.280) (n) | 52 | ND | ND | 29 | |||
IgA, IgG, IgM (%) | 7.6 | 0 |